Polypore Mushroom Mycelia for Treatment of Active COVID-19 Infection: A Randomized Clinical Trial

Publication date: Jun 08, 2026

Use of fungal mycelia, which has antiviral properties, constitutes a novel strategy for addressing existing and newly emerging viral diseases. We evaluated safety and feasibility of fungal mycelia (Fomitopsis officinalis and Trametes versicolor, FoTv) for treatment of COVID-19 and assessed its antiviral effects and potential to reduce symptoms. In a randomized, double-blind, placebo-controlled, dual site (UCSD/UCLA medical centers) clinical trial we examined non-hospitalized patients who contracted mild-to-moderate COVID-19 [≤] 96 hours, and experienced symptom onset [≤] nine days, before enrollment. FoTv was safe, well-tolerated, and feasible for COVID-19 treatment. Minor differences in biochemical markers were observed between groups (26 FoTv, 24 Placebo). FoTv significantly reduced the number and severity of symptoms, particularly sore throat/cough, and in vitro SARS-CoV-2 (pseudovirus) cellular infection. In conclusion, FoTv was safe and reduced COVID-19 symptoms and cellular viral infection. Future studies should investigate therapeutic benefits of fungal mycelia for SARS-CoV-2 and other viruses. Clinicaltrials.gov registration:NCT04667247.

PDF

Concepts Keywords
Fungi California
Hepatic Certified
Lessons Covid
Orthopoxviruses2124 Fotv
Ucla Funder
Granted
International
License
Licenseit
Medrxiv
Peer
Preprint
Symptoms
Treatment
Viral

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Infection
disease MESH viral diseases
disease MESH sore throat
disease MESH cough
disease MESH David
disease MESH influenza
disease MESH emergencies
disease MESH dengue fever
disease MESH emerging infectious diseases
disease MESH avian influenza
disease MESH conjunctivitis
disease MESH respiratory failure
drug DRUGBANK Trametes versicolor fruiting body
disease MESH included
disease MESH liver failure
drug DRUGBANK Ethanol
drug DRUGBANK Medical Cannabis
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Ivermectin
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Sodium Chloride
drug DRUGBANK Urea
drug DRUGBANK Nitrogen
drug DRUGBANK Alkaline Phosphatase
disease MESH ALP
drug DRUGBANK Prothrombin
disease MESH fever
disease MESH fatigue
disease MESH aches
disease MESH breath shortness
disease MESH runny nose
disease MESH taste loss
disease MESH headache

Download Document

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *